Dual-target GPC3 and B7-H3 CAR‑NK therapy for advanced liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 1/2, single‑group trial of an allogeneic donor‑derived NK cell product engineered with a dual CAR against GPC3 and B7‑H3, given after standard fludarabine/cyclophosphamide lymphodepletion. Phase 1 uses dose escalation to define safety, dose‑limiting toxicities, and the recommended phase 2 dose, and phase 2 expands at that dose to estimate preliminary activity. Enrollment requires tumor tissue showing GPC3 and B7‑H3 expression above prespecified cutoffs and measurable disease by RECIST 1.1, with careful hepatic function and performance-status eligibility. Clinical endpoints center on safety and feasibility in phase 1 and early anti‑tumor responses and durability in phase 2.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 to 75 years.
* Histologically or cytologically confirmed HCC, or radiologically diagnosed HCC with mandatory tissue confirmation of target expression before enrollment.
* Unresectable, locally advanced, or metastatic HCC not amenable to curative surgery, transplant, or further locoregional therapy; BCLC stage C, or stage B that is not suitable for or has progressed after locoregional therapy.
* Disease progression on, intolerance to, or ineligibility for at least 1 prior standard systemic regimen.
* Central pathology showing GPC3 positivity in \>=25% of viable tumor cells by IHC and B7-H3 positivity in \>=10% of tumor cells and/or tumor-associated stromal/vascular cells by IHC.
* At least 1 measurable lesion by RECIST 1.1; intrahepatic lesions must be assessable by contrast-enhanced triphasic CT or MRI.
* ECOG performance status 0 to 1.
* Child-Pugh class A or stable Child-Pugh B7 without uncontrolled ascites or recent encephalopathy.
* Estimated life expectancy \>=12 weeks.
* Adequate organ function: WBC \>=2.5 x 10\^9/L; platelets \>=60 x 10\^9/L; hemoglobin \>=9 g/dL; serum albumin \>=30 g/L; creatinine clearance \>=40 mL/min; AST/ALT \<=5 x ULN; total bilirubin \<=2.5 x ULN; INR/prothrombin time within protocol-defined range.
* If HBsAg positive or anti-HBc positive, HBV DNA must be \<200 IU/mL and the participant must be on appropriate antiviral therapy before lymphodepletion. Controlled HCV is allowed if per protocol.
* Negative serum pregnancy test for participants of childbearing potential and agreement to effective contraception.
* Ability to understand and sign informed consent.

Exclusion Criteria:

* Prior gene-modified cellular therapy (for example prior CAR-T, CAR-NK, or TCR-engineered therapy) within the protocol-defined washout period or with unresolved clinically significant toxicity.
* Active, uncontrolled infection, including uncontrolled bacterial, viral, or fungal infection; uncontrolled HIV; active HBV or HCV with uncontrolled viral load; or active tuberculosis.
* Known active CNS metastases or leptomeningeal disease requiring escalating steroids or urgent local intervention.
* Liver transplant or other solid-organ transplant history, or current requirement for chronic immunosuppression.
* Clinically significant ascites requiring frequent drainage, grade \>=2 hepatic encephalopathy within 4 weeks, or recent clinically significant variceal/GI bleeding.
* Extensive liver replacement by tumor (for example \>=70%) or complete major portal vein/hepatic venous obstruction judged to create excessive treatment risk.
* Major surgery, locoregional therapy, radiotherapy, or systemic anticancer therapy too close to lymphodepletion per protocol-defined washout period.
* Active autoimmune disease requiring systemic immunosuppressive therapy, or chronic systemic corticosteroids above protocol threshold.
* Clinically significant cardiovascular disease (recent myocardial infarction, unstable arrhythmia, uncontrolled heart failure), uncontrolled pulmonary disease, or other serious comorbidity that materially increases study risk.
* Pregnant or breastfeeding.
* Any other active malignancy that is progressing or requires current systemic treatment.
* Any medical or psychiatric condition that, in the investigator's judgment, would compromise safety, protocol compliance, or interpretation of results.

Where it's running

• Peking University Shenzhen Hospital
  Shenzhen, Guangdong, China Recruiting

Study contacts

• Study coordinator: Seni S Lu, Phd
• Email: Seni-Lu@beijing-biotech.com
• Phone: +86 13076790030

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Super CAR-T therapy for GPC3-positive advanced liver cancer

  This trial tests a single infusion of Super CAR-T cell therapy in adults with advanced, GPC3-positive hepatocellular carcinoma who have failed at least two standard treatments.

  Recruiting Phase 1 Guangzhou FineImmune Biotechnology Co., LTD. · Guangzhou, Gaungdong · NCT07493044

• Comparing first-line immunotherapy combinations for advanced liver cancer

  We will try different first-line immunotherapy combinations to see which works best for people with advanced hepatocellular carcinoma.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07147101

• Autologous neoantigen T-cell therapy for advanced liver cancer

  This treatment tries a personalized neoantigen-specific T-cell therapy for people with advanced hepatocellular carcinoma who have not responded to two or more systemic treatments.

  Recruiting Phase 1/2 Zhejiang University · Hangzhou, Zhejiang · NCT07123545

• Streamlined radioembolization for cholangiocarcinoma and metastatic liver cancer

  This study tests whether skipping the pre-procedure nuclear lung scan is safe and speeds up treatment for adults with small (≤7 cm), limited-number metastatic liver tumors or intrahepatic cholangiocarcinoma.

  Recruiting Seoul National University Hospital · Goyang-si and 3 other locations · NCT07043387

• CG-102-12C for GPC3-positive advanced liver cancer

  This will test whether a single infusion of CG-102-12C can help people aged 18–75 with GPC3‑positive advanced hepatocellular carcinoma who did not respond to standard systemic treatments.

  Recruiting Zhejiang University · Hangzhou, Zhejiang and 1 other locations · NCT07039201

• Personalized mRNA therapy for advanced liver cancer

  This study is testing a new personalized mRNA therapy combined with other treatments to see if it can help people with advanced liver cancer feel better.

  Recruiting Phase 1/2 Zhejiang University · Hangzhou, Zhejiang · NCT06995105

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.